Treatment Algorithms: Alzheimer's Disease – Off-label prescribing driven by dearth of treatment options

| comments

The use of combination therapy increases at second line and in more severe patients. In the US, combination therapy is apparent even at first-line treatment of moderate and severe Alzheimer’s disease, indicating that neurologists are willing to initiate therapy of an advanced patient with a cholinesterase inhibitor and memantine.

Your key questions answered
·         How does each drug’s patient share vary by disease severity and line of therapy?
·         What can be done to influence the patient pathway to increase market share?
·         What is the realistic patient population that a new market entrant can target?
·         How has generic donepezil affected prescribing behaviors in the US?

Request a Sample for or Inquire before buying the report@

Alzheimer's Disease

Features and benefits
·         Quantify the prevalent, diagnosed, and treated Alzheimer’s disease patient populations in each of the seven major markets.
·         Analyze physician prescribing habits by disease severity and line of therapy.
·         Understand how treatment and compliance rates vary according to disease severity.
·         Identify opportunities for increasing market share through effective product positioning.

Major points covered in Table of Contents of this report include:
Executive summary

See More Healthcare Market Research Reports

Report Details :
Published:   March 2012
No. of Pages:  
Price:    Single User License - US $ 7600
                Corporate user License- US $ 19000
Share this article :

Post a Comment

Support : Creating Website | Johny Template | Mas Template
Copyright © 2011. Market Forecasts - All Rights Reserved
Template Created by Creating Website Published by Mas Template
Proudly powered by Blogger